阿比特龙强化治疗对新诊断前列腺癌骨折相关住院的影响
基于STAMPEDE平台两项随机3期试验的二次分析,纳入3893例高危非转移或转移性前列腺癌患者,其中3102例有英格兰HES链接数据。结果显示,在转移性疾病中,SOC+AAP和SOC+AAP+Enza较SOC alone显著降低5年骨折相关住院累积发生率,而非转移性疾病中无显著差异。
要点
- 在转移性前列腺癌中,阿比特龙为基础的治疗强化未增加骨折相关住院,反而显著降低。
- 非转移性前列腺癌中,阿比特龙强化与标准治疗在骨折相关住院上无显著差异。
- 该分析提示阿比特龙可能通过改善转移性骨病控制而降低骨折风险。
核心结论
- 阿比特龙为基础的治疗强化与标准治疗相比未增加骨折相关住院。
- 在转移性疾病中,阿比特龙降低而非增加骨折风险,最可能反映转移性骨病控制改善。
研究设计与样本
- 对STAMPEDE平台两项随机3期试验的二次分析。
- 2011年11月至2016年3月,3893例高危非转移(M0)或转移(M1)前列腺癌患者随机分配。
- 英格兰3102例患者的HES链接数据可用。
- 采用预设编码框架识别骨折相关住院,使用灵活参数竞争风险模型估计5年累积发生率和亚分布风险比(SDHR),死亡为竞争风险。
主要发现
- 在M1疾病中,SOC+AAP组5年骨折相关住院发生率为22%,SOC alone组为30%(SDHR 0.77,95%CI 0.59-0.99;p=0.04)。
- 在M1疾病中,SOC+AAP+Enza组5年骨折相关住院发生率为28%,SOC alone组为38%(SDHR 0.69,95%CI 0.54-0.88;p=0.002)。
- 在M0患者中未观察到显著差异。
临床怎么用
- 对于转移性前列腺癌患者,采用阿比特龙强化治疗时无需过度担忧骨折相关住院风险增加。
- 在非转移性患者中,阿比特龙强化对骨折相关住院的影响与标准治疗无显著差异。
局限性
- 排除未住院的骨折可能低估总骨折负担。
- 缺乏基线骨折风险评估包括骨密度。
- 骨保护治疗的纵向使用情况未充分控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate cancer (PCa) patients are at increased fracture risk due to the need for androgen deprivation therapy (ADT) and progressive bone metastases. Previous meta-analyses of randomised controlled trials suggest that androgen receptor pathway inhibitors (ARPIs) increase fracture risk. OBJECTIVE: We assessed the impact of abiraterone-based treatment intensification on fracture-related hospitalisation (FRH) within the STAMPEDE trial platform. DESIGN, SETTING AND PARTICIPANTS: We performed a secondary analysis of two STAMPEDE trials in patients with high-risk non-metastatic (M0) or metastatic (M1) disease. INTERVENTIONS: Patients were allocated to either standard of care (SOC) or SOC plus abiraterone with prednisolone (AAP) or, in a later comparison, SOC+AAP with enzalutamide (Enza). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A prespecified coding framework within Hospital Episode Statistics (HES) identified FRHs. Flexible parametric competing-risk models estimated 5-year cumulative incidence of FRH and sub-distribution hazard ratios (SDHR), with death as a competing risk. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Between Nov 2011 and Mar 2016, 3893 patients were randomised to the STAMPEDE AAP±Enza trials. Linked HES data were available for 3102 patients in England. In M1 disease, 5-year FRH incidence was significantly lower with SOC + AAP than SOC alone (22% vs 30%; SDHR 0.77, 95%CI 0.59-0.99; p = 0.04) and with SOC + AAP + Enza than SOC alone (28% vs 38%; SDHR 0.69, 95%CI 0.54-0.88; p = 0.002). No significant difference was observed in M0 patients. Limitations include potential under-estimation of total fracture burden by exclusion of non-hospitalised fractures, lack of baseline assessment of fracture risk including bone mineral density, and longitudinal use of bone-protective therapy. CONCLUSIONS: Abiraterone-based treatment intensification did not increase FRH compared to SOC alone. In M1 disease, abiraterone reduced rather than augmented fracture risk, most plausibly reflecting improved metastatic bone disease control.
引用
- Gray S, Dutey-Magni P, Jones C, et al. Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform. Eur Urol. 2026. PMID: 42711192. doi:10.1016/j.eururo.2026.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。